Abstract
The spleen tyrosine kinase Syk is an enigmatic protein tyrosine kinase functional in a number of diverse cellular processes. It is best known as a non receptor protein tyrosine kinase involved in signal transduction in cells of hematopoietic origin and plays a crucial role in signaling in most of these cells. It is involved in B and T-cell function, platelet aggregation, mast cell signaling, neutrophils and macrophages. Recently it has been found in tissues outside of the hematopoietic lineage. Perhaps the most interesting non-traditional role of Syk is that of a potential tumor suppressor in breast cancer. Absence of Syk protein in primary breast tumors is correlated with poor outcomes. Syk deficient cells have increased motility which is restored to normalcy by replacement with wild-type Syk. Syk also associates with the actin and tubulin cytoskeleton and is an α-tubulin kinase. The central role that Syk has in a number of cellular processes makes it an ideal starting point for broad therapeutic targeting.
Keywords: spleen tyrosine kinase, tyrosine kinase inhibitor, syk protein, breast tumors
Current Pharmaceutical Design
Title: The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Volume: 10 Issue: 15
Author(s): Christopher S. Navara
Affiliation:
Keywords: spleen tyrosine kinase, tyrosine kinase inhibitor, syk protein, breast tumors
Abstract: The spleen tyrosine kinase Syk is an enigmatic protein tyrosine kinase functional in a number of diverse cellular processes. It is best known as a non receptor protein tyrosine kinase involved in signal transduction in cells of hematopoietic origin and plays a crucial role in signaling in most of these cells. It is involved in B and T-cell function, platelet aggregation, mast cell signaling, neutrophils and macrophages. Recently it has been found in tissues outside of the hematopoietic lineage. Perhaps the most interesting non-traditional role of Syk is that of a potential tumor suppressor in breast cancer. Absence of Syk protein in primary breast tumors is correlated with poor outcomes. Syk deficient cells have increased motility which is restored to normalcy by replacement with wild-type Syk. Syk also associates with the actin and tubulin cytoskeleton and is an α-tubulin kinase. The central role that Syk has in a number of cellular processes makes it an ideal starting point for broad therapeutic targeting.
Export Options
About this article
Cite this article as:
Navara S. Christopher, The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy, Current Pharmaceutical Design 2004; 10 (15) . https://dx.doi.org/10.2174/1381612043384493
DOI https://dx.doi.org/10.2174/1381612043384493 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer’s Disease and Other Tauopathies
Pharmaceutical Nanotechnology Annexins Bend Wound Edges during Plasma Membrane Repair
Current Medicinal Chemistry Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Editorial
Current Medical Imaging Targeted Drug Delivery Systems for Lung Macrophages
Current Drug Targets Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design Ozone Dosage Effect on C6 Cell Growth: in Vitro and in Vivo Tests
Anti-Cancer Agents in Medicinal Chemistry Future Oncotargets: Targeting Overexpressed Conserved Protein Targets in Androgen Independent Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Blood-brain Barrier Drug Discovery for Central Nervous System Infections
Current Drug Targets - Infectious Disorders Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy: A Systematic Review
Current Stem Cell Research & Therapy Micropropagation: A Tool for the Production of High Quality Plant-based Medicines
Current Pharmaceutical Biotechnology The Therapeutic Potential of Stem Cells in Amyotrophic Lateral Sclerosis
Current Signal Transduction Therapy Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Synthesis and Evaluation of Estradiol Derivatives as Anti-Breast Cancer Agents
Letters in Drug Design & Discovery Severe Adenovirus Pneumonia Followed by Bacterial Septicaemia: Relevance of Co-Infections in Allogeneic Hematopoietic Stem Cell Transplantation
Infectious Disorders - Drug Targets